2月10日上午，聊城华厦眼科（301267）医院首例EVO+ICL(V5)新型晶体植入手术成功开展，这是全国首批此类手术，标志着聊城华厦眼科医院在屈光矫 正领域实现了技术再升级，也为更多近视患者带来了更精准、舒适的摘镜新选择。 据了解，本次手术的患者是一名在校大学生，21岁。该患者的眼部屈光情况较为复杂，双眼近视度数均近1000度，并伴有200余度散光(右眼：875度近视 +250度散光；左眼：975度近视+225度散光)。 未来，医院也将持续深耕屈光领域，依托专家团队与全流程质量管理体系，为不同视力困扰的人群，尤其是高度近视群体，提供更先进、高质且个性化的 视觉健康解决方案，助力更多人实现清晰视界的梦想。 本次手术由聊城华厦眼科医院屈光手术专家于瑞云亲自主刀。术前，聊城华厦眼科屈光团队为患者进行了全面细致的眼部检查，结合其职业特点和眼部条 件，量身定制了EVO+ICL(V5)晶体植入手术方案，并详细讲解了手术流程、术式优势及术后注意事项，充分缓解患者紧张情绪。 作为拥有10余年屈光诊疗经验，瑞士STAAR EVO-ICL认证医师的专家，于瑞云院长以精湛娴熟的技术，十分钟左右便完成了V5晶体的精准植入，术中患 ...

近日，医院已成功开展了无锡地区首台EVO+ICL（V5）晶体植入手术。该手术由无锡华厦眼科医院近 视手术专家顾勇院长主刀完成，标志着无锡近视矫正迈入更精准、更个性化的新阶段，将为众多受夜间 视力困扰的近视患者带来新的解决方案。 2026年1月，被业界誉为"夜间视觉优化版"的EVO+ICL（V5）——新一代可植入式接触镜正式进入无 锡。无锡华厦眼科（301267）医院成为无锡率先引进这一技术的医疗机构。 患者故事，从夜间困扰到清晰视界 林女士是无锡华厦眼科首位接受EVO+ICL（V5）晶体植入的近视患者。作为高度近视者，她的生活深 受厚重镜片影响，而夜跑这一放松方式也因夜间视力问题变得困难。 然而，高度近视已成了她享受夜间活力的最大阻碍。框架眼镜在运动中太不方便，但更困扰她的是夜间 视力——路灯的光晕、球场灯光的眩光，让她的视界一片模糊，不仅影响发挥，也存在安全隐患。对夜 间视觉品质的高要求，让她对常规近视矫正手术心存疑虑。 了解到无锡华厦眼科医院引进的EVO+ICL（V5）晶体专门针对夜间视觉优化时，林女士看到了希望。 经检查，她的较大暗瞳条件恰好与EVO+ICL（V5）晶体扩大光学区的设计优势相匹配。 手术 ...

证券日报网讯2月4日，华厦眼科（301267）在互动平台回答投资者提问时表示，公司始终关注眼科诊疗 新设备、新技术的发展，积极引进国内外先进的眼科诊疗技术和设备。在国产设备方面，公司与国内主 要的设备厂商均建立了长期稳定的联系，未来公司将根据临床应用需求及技术成熟度，逐步推进国产设 备的引进和应用，为患者提供优质、多元化的诊疗服务。 ...

Core Viewpoint - Huaxia Eye Hospital Group has been awarded the "2025 Innovation Brand Award" at the 8th Golden Jubilee Awards for its systematic, leading, and effective brand innovation practices [1][3] Group 1: Awards and Recognition - The "Golden Jubilee Award" is recognized for its objective, fair, and authoritative research attributes, based on big data analysis of thousands of companies [3] - This award follows Huaxia Eye's previous recognitions, including being listed in the "Top 50 New Brands" of the "China Listed Companies Brand Value List" and receiving accolades such as "Top Ten Trusted Health Brands" and "Outstanding Brand Management Company" [3] Group 2: Brand Innovation and Strategy - Brand innovation is essential for corporate growth and serves as a stabilizing force against market uncertainties [5] - Huaxia Eye integrates brand building into its "medical, education, and research" collaborative development system, enhancing brand connotation and soft power [5] - The company is implementing a "1236" strategy to accelerate the establishment of a world-renowned ophthalmology center and global service network by 2025 [5] Group 3: Technological Advancements - Huaxia Eye has introduced advanced technologies such as the new generation of robotic all-laser LASIK VISUMAX800 and the SMILE pro minimally invasive surgery, becoming one of the first clinical application units for EVO+ ICL (V5) in China [6] - The company has completed the localized deployment of the DeepSeek model and launched the first domestic AI self-test tool for dry eyes, enhancing eye health management [6] Group 4: Social Responsibility and Community Engagement - The company has initiated various social responsibility programs, including the "Eye Health Care Plan for Journalists" and the publication of the first "Xiamen City Journalists Eye Health White Paper" [6] - Huaxia Eye's "Huaxia Bright Action" charity brand has conducted medical assistance in countries along the "Belt and Road" and provided support in regions like Ningxia, Qinghai, Xinjiang, and Tibet [7] Group 5: Future Outlook - Huaxia Eye aims to continue its commitment to innovation and patient-centered care, contributing significantly to the development of the ophthalmology sector in China [9]

Core Viewpoint - A new ophthalmology clinic, Xiamen Tong'an Huaxia Eye Hospital Co., Ltd., has been established with a registered capital of 5 million RMB, fully owned by Xiamen Huaxia Optometry Center Co., Ltd. [1] Company Summary - The legal representative of the new clinic is Chen Xiangdong [1] - The registered capital of the clinic is 5 million RMB [1] - The clinic is located at 102, 104 Nanmen Road, Tong'an District, Xiamen [1] - The company type is a limited liability company, wholly owned by a natural person [1] - The business license allows for a variety of medical and retail services, including medical services, medical device sales, and retail of health products [1] Industry Summary - The clinic operates in the healthcare and social work sector, specifically under the hospital category [1] - The business scope includes medical services, sales of various medical and personal hygiene products, and food sales (only pre-packaged food) [1] - The operational period is set until January 22, 2026, with no fixed end date [1]

Core Insights - The 2025 TBI Top Brand Innovation Awards recognized Huaxia Eye Hospital for its comprehensive brand advantages, winning the "Annual Brand Award" [1][4] Group 1: Award Significance - The TBI Top Brand Innovation Awards, now in its sixth year, is a prestigious honor in China, focusing on brand growth paths in the digital age and recognizing brands with innovation, foresight, and practical value [4] - This year's awards attracted participation from 578 companies, including major brands like Nestlé, Volkswagen, and Coca-Cola, showcasing 1,744 innovative works [4] Group 2: Brand Development - Huaxia Eye Hospital has successfully transitioned from "brand awareness" to "brand value," emphasizing a patient-centered approach and a commitment to enhancing medical, social, and ecological value [7] - The hospital integrates medical education and research, being one of the few large eye care chains in China with "double three A" certifications and three international ophthalmology academicians [8] Group 3: Social Responsibility - Huaxia Eye Hospital has a long-standing commitment to social value, conducting free eye care initiatives in countries along the Belt and Road, and has assisted in screening 20 million people for myopia prevention [10] - The hospital has launched various public health initiatives, including an AI self-test tool for dry eye, reaching 360 million patients [10] Group 4: Ecological Value - The hospital is expanding its brand through cross-industry collaborations, such as a joint public welfare initiative with Nova Coffee, promoting a "consumption equals public welfare" model [12] - Huaxia Eye Hospital is building a sustainable brand ecosystem by integrating medical, social, and ecological values, aiming for continuous evolution and collaboration [12][14]

Core Viewpoint - The "domestically produced all-laser refractive surgery machine" developed by Professor Zhang Mingchang's team has been recognized as one of the "Top Ten Original Advances in Ophthalmology in China for 2025," marking a significant breakthrough in the field of high-end laser treatment equipment for myopia refractive surgery in China [1][7]. Group 1: Research and Development Achievements - Professor Zhang Mingchang's team has been dedicated to the innovation and research of ocular surface diseases and refractive treatment technologies [3][9]. - The team previously developed the "tear lipid content detection test strip," which was included in the "Top Ten Advances in Chinese Ophthalmology" in 2021 [3][9]. Group 2: Technological Breakthroughs - The newly developed device achieves significant technological breakthroughs in laser energy control, beam positioning accuracy, and surgical process stability, specifically designed for myopia refractive surgery [5][11]. - The core optical system and intelligent control platform of the device are entirely developed domestically, breaking the long-standing reliance on imported equipment [5][11]. Group 3: Market Impact and Future Prospects - The device is expected to provide higher quality and more accessible high-end refractive surgery options for myopia patients, potentially lowering surgical costs and benefiting many individuals seeking vision correction [5][11]. - The development and transformation of this achievement exemplify successful collaboration between medical engineering and industry-academia partnerships, promoting the localization of high-end ophthalmic treatment equipment and supporting the self-control and technological upgrades of the related industry chain [12]. - Looking ahead, the team plans to deepen collaboration with the industry to promote more original and leading technologies for clinical application, contributing to the high-quality development of eye health in China and supporting the "Healthy China" strategic goal [14].

Core Insights - The biopharmaceutical industry in China is a strategic emerging industry, crucial for public health, technological innovation, and enhancing national pharmaceutical autonomy. The market size is projected to grow from CNY 4,210 billion in 2022 to CNY 8,000 billion by 2028, with an annual growth rate stabilizing between 10%-12% [1][2][23]. Industry Overview - In 2020, the biopharmaceutical market in China was valued at CNY 3,457 billion, increasing to CNY 4,100 billion in 2021, representing an 18.6% year-on-year growth. However, growth slowed to 2.68% in 2022, with a slight increase to CNY 4,210 billion [1][2]. - The industry is segmented into upstream (raw materials and medical devices), midstream (drug synthesis and production), and downstream (drug distribution). Biopharmaceuticals and chemical drugs have higher profit margins, with biopharmaceutical companies reporting gross margins of 80%-86% [2][4]. Xiamen Biopharmaceutical Industry - Xiamen is a key hub for biopharmaceutical industry development, recognized as a national strategic emerging industry cluster. The local government has implemented various supportive policies since 2016, focusing on innovation and industrialization [6][9]. - The industrial output value of Xiamen's biopharmaceutical sector reached CNY 1,045.87 billion in 2022, with a slight decline to CNY 847 billion in 2023, and is projected to stabilize around CNY 840 billion in 2024 [17][18]. Policy Environment - Xiamen's government has introduced multiple measures to support the biopharmaceutical industry, including financial incentives for R&D and commercialization, with significant rewards for new drug development and medical device innovation [9][26]. - The city aims to establish a CNY 100 billion venture capital fund and enhance the entire process from R&D to clinical application by 2025 [23][26]. Future Outlook - By 2025, Xiamen plans to significantly increase the number of registered biopharmaceutical companies, with projections indicating over 2,200 registered firms, marking a notable rise from previous years [18]. - The city aims to develop a CNY 700 billion biopharmaceutical industry chain, supported by specialized parks and a focus on various sub-sectors, including biopharmaceuticals and medical devices [23][26].

Group 1 - The core point of the article is that Huaxia Eye Hospital announced the resolutions passed during the first meeting of its fourth board of directors, including the election of the chairman and the appointment of the general manager [1] Group 2 - The company approved multiple resolutions, including the election of the chairman of the fourth board of directors and the election of members for the specialized committees [1] - The announcement reflects the company's governance structure and leadership changes, which may impact its strategic direction [1] - The appointment of the general manager is a significant step in the company's operational management [1]

Core Viewpoint - Huaxia Eye Hospital announced the approval of the proposals for the election of the fourth board of directors, including both non-independent and independent director candidates at the first extraordinary shareholders' meeting of 2026 [2] Group 1 - The company held its first extraordinary shareholders' meeting of 2026 on January 14 [2] - The proposals for the election of the fourth board of directors were approved during this meeting [2] - The proposals included nominations for both non-independent and independent director candidates [2]